Business Summary: Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Vanda Pharmaceuticals Inc. revenues increased 3% to $198.8M. Net loss totaled $18.9M vs. income of $2.5M. Revenues reflect PONVORY segment increase from $1.6M to $27.8M, Fanapt segment increase of 4% to $94.3M. Net loss reflects Selling, General and administrative - increase of 33% to $135M (expense), Intangible asset amortization increase from $2.1M to $7.3M (expense).